Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | nuclear factor, erythroid 2-like 2 | Starlite/ChEMBL | No references |
Homo sapiens | APEX nuclease (multifunctional DNA repair enzyme) 1 | Starlite/ChEMBL | No references |
Homo sapiens | SMAD family member 2 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | MH2 domain containing protein | SMAD family member 2 | 467 aa | 405 aa | 31.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0043 | 0.2567 | 1 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0023 | 0.1036 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.2567 | 1 |
Schistosoma mansoni | ap endonuclease | 0.0023 | 0.1036 | 0.3833 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.2567 | 1 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0023 | 0.1036 | 0.5 |
Brugia malayi | exodeoxyribonuclease III family protein | 0.0023 | 0.1036 | 0.0959 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.0023 | 0.1036 | 0.5 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.0023 | 0.1036 | 1 |
Brugia malayi | Cytochrome P450 family protein | 0.0026 | 0.127 | 0.1196 |
Schistosoma mansoni | hypothetical protein | 0.0043 | 0.2567 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.2567 | 1 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0016 | 0.0517 | 0.0517 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.2567 | 1 |
Brugia malayi | hypothetical protein | 0.0043 | 0.2567 | 0.2503 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0043 | 0.2567 | 1 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0144 | 1 | 1 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0043 | 0.2567 | 1 |
Loa Loa (eye worm) | Smad1 | 0.001 | 0.0085 | 0.0085 |
Loa Loa (eye worm) | CYP4Cod1 | 0.0016 | 0.0517 | 0.0517 |
Loa Loa (eye worm) | exodeoxyribonuclease III family protein | 0.0023 | 0.1036 | 0.1036 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0023 | 0.1036 | 0.5 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0023 | 0.1036 | 1 |
Brugia malayi | Cytochrome P450 family protein | 0.0016 | 0.0517 | 0.0436 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0026 | 0.127 | 0.127 |
Toxoplasma gondii | exonuclease III APE | 0.0023 | 0.1036 | 0.5 |
Schistosoma mansoni | ap endonuclease | 0.0023 | 0.1036 | 0.3833 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0144 | 1 | 1 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0023 | 0.1036 | 0.5 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.001 | 0.0085 | 0.0085 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0016 | 0.0517 | 0.0517 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0023 | 0.1036 | 0.5 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0023 | 0.1036 | 0.5 |
Loa Loa (eye worm) | MH1 domain-containing protein | 0.001 | 0.0085 | 0.0085 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.0023 | 0.1036 | 1 |
Echinococcus granulosus | DNA apurinic or apyrimidinic site lyase | 0.0023 | 0.1036 | 0.3833 |
Brugia malayi | Cytochrome P450 family protein | 0.0016 | 0.0517 | 0.0436 |
Echinococcus multilocularis | DNA (apurinic or apyrimidinic site) lyase | 0.0023 | 0.1036 | 0.3833 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0023 | 0.1036 | 0.5 |
Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.0023 | 0.1036 | 1 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.0023 | 0.1036 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 8.9125 uM | PubChem BioAssay. qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 10 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 12.9953 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | 25.9185 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125] | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID540273] | ChEMBL. | No reference |
Potency (functional) | 37.933 uM | PUBCHEM_BIOASSAY: qHTS profiling assay for firefly luciferase inhibitor/activator using purified enzyme and Km concentrations of substrates (counterscreen for miR-21 project). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2288, AID2289, AID2598, AID411] | ChEMBL. | No reference |
Potency (functional) | = 50.1187 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of DNA Polymerase Beta. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.